Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 5, 2012

View Archived Issues

Mitsubishi Tanabe Pharma offers overview of second quarter 2012

Encouraging phase III results presented for Biocon's insulin biosimilar

Cubist Pharmaceuticals begins phase III program for CB-5945

European Commission denies marketing authorization for taliglucerase alfa

Phase I results reported for ICT-107 in glioblastoma multiforme

British and French group presents novel vaccines for AIDS

Qilu Pharmaceutical discloses novel EGFR inhibitors

Shanghai Allist Pharmaceutical patents new PI3K inhibitors

Novel tyrosine-protein kinase inhibitors prepared at Pharmascience

Phase II study of GS-7340 meets 24-week primary objective

Lundbeck prepares new antibodies for Alzheimer's disease

New CSF-1 receptor inhibitors divulged by Pharmascience

Sanofi presents pipeline highlights of third quarter 2012

Degarelix evaluated in women undergoing in vitro fertilization

Immune Response BioPharma publishes full results from phase III study of HIV vaccine

Vertex enters agreements for VX-135 combination studies

Lisdexamfetamine mesilate proves beneficial in cognitively impaired MS patients

FDA requests additional information in CRL for lixivaptan NDA

AlphaCore obtains EMA orphan drug designation for ACP-501

Aerie reports topline data from phase IIa studies of its ROCK inhibitors

Glybera gene therapy approved by the European Commission

Hutchison MediPharma begins phase I study of novel EGFR inhibitor

BAX B-01 shows promise in model of proliferative nephritis

Phase III trial of Adcetris in advanced Hodgkin's lymphoma begins

Keryx Biopharmaceuticals commences phase II study of Zerenex

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
AI drug developer Insilico to raise $292 million in Hong Kong IPO
BioWorld
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...